Boehringer Ingelheim Commits to Veeva Vault CRM
Boehringer Ingelheim, a top 20 global biopharma company, has committed to implementing Veeva Vault CRM (NYSE: VEEV) as its commercial foundation. The company aims to launch up to 25 new treatments by 2030 and plans to expand on its existing Veeva Commercial Cloud solutions, One Medicine, and Amplify platforms. This decision builds upon their long-standing partnership where Veeva has served as their global CRM standard. The implementation is expected to help transform commercial operations, accelerate launch processes, and enable personalized customer engagement.
Boehringer Ingelheim, una delle prime 20 aziende biopharma a livello globale, si è impegnata ad implementare Veeva Vault CRM (NYSE: VEEV) come base commerciale. L'azienda mira a lanciare fino a 25 nuovi trattamenti entro il 2030 e prevede di ampliare le soluzioni già esistenti nel Veeva Commercial Cloud, nelle piattaforme One Medicine e Amplify. Questa decisione si basa sulla loro lunga partnership, in cui Veeva ha servito come standard globale per il CRM. L'implementazione è prevista per trasformare le operazioni commerciali, accelerare i processi di lancio e consentire un coinvolgimento personalizzato dei clienti.
Boehringer Ingelheim, una de las 20 principales empresas de biopharma a nivel mundial, se ha comprometido a implementar Veeva Vault CRM (NYSE: VEEV) como su base comercial. La compañía tiene el objetivo de lanzar hasta 25 nuevos tratamientos para 2030 y planea expandir sus soluciones existentes en Veeva Commercial Cloud, así como en las plataformas One Medicine y Amplify. Esta decisión se basa en su asociación a largo plazo, donde Veeva ha servido como estándar global para su CRM. Se espera que la implementación transforme las operaciones comerciales, acelere los procesos de lanzamiento y permita una interacción personalizada con los clientes.
보링거인겔하임, 글로벌 바이오제약 기업 20위 안에 드는 회사가 Veeva Vault CRM (NYSE: VEEV)을 상업적 기반으로 구현하기로 약속했습니다. 회사는 2030년까지 25개의 새로운 치료법을 출시할 계획이며, 기존의 Veeva Commercial Cloud 솔루션과 One Medicine, Amplify 플랫폼을 확대할 예정입니다. 이번 결정은 Veeva가 글로벌 CRM 표준으로 활동한 오랜 파트너십을 바탕으로 합니다. 이 구현은 상업 운영을 혁신하고, 출시 프로세스를 가속화하며, 맞춤형 고객 참여를 가능하게 할 것으로 기대됩니다.
Boehringer Ingelheim, une des 20 principales entreprises biopharmaceutiques mondiales, s'est engagée à mettre en œuvre Veeva Vault CRM (NYSE: VEEV) comme fondement commercial. L'entreprise vise à lancer jusqu'à 25 nouveaux traitements d'ici 2030 et prévoit d'élargir ses solutions Veeva Commercial Cloud existantes ainsi que les plateformes One Medicine et Amplify. Cette décision s'appuie sur leur partenariat de longue date, au cours duquel Veeva a servi de standard CRM mondial. La mise en œuvre devrait contribuer à transformer les opérations commerciales, à accélérer les processus de lancement et à permettre un engagement client personnalisé.
Boehringer Ingelheim, ein führendes biopharmazeutisches Unternehmen unter den Top 20 weltweit, hat sich verpflichtet, Veeva Vault CRM (NYSE: VEEV) als kommerzielle Grundlage umzusetzen. Das Unternehmen plant, bis 2030 bis zu 25 neue Therapien einzuführen und plant, seine bestehenden Lösungen des Veeva Commercial Cloud, One Medicine und Amplify-Plattformen auszubauen. Diese Entscheidung basiert auf ihrer langjährigen Partnerschaft, in der Veeva als globaler CRM-Standard fungiert hat. Die Implementierung wird voraussichtlich die kommerziellen Abläufe transformieren, die Einführungsgeschwindigkeit beschleunigen und personalisierte Kundeninteraktionen ermöglichen.
- Secured commitment from a top 20 global biopharma company
- Client plans significant expansion with 25 new treatment launches by 2030
- Deepening relationship with existing major customer
- Expansion of product usage beyond current Commercial Cloud solutions
- None.
Insights
The commitment from Boehringer Ingelheim, a top 20 global biopharma company, to adopt Veeva Vault CRM represents a significant enterprise win for Veeva Systems. This deal reinforces Veeva's position as the leading CRM provider in the life sciences sector and demonstrates strong customer retention. With Boehringer planning 25 new treatment launches by 2030, this long-term commitment suggests substantial recurring revenue potential.
The expansion of Veeva's footprint within Boehringer's tech stack, including Commercial Cloud solutions and Development Cloud, indicates deep platform entrenchment and potential for increased revenue per customer. This type of enterprise-wide adoption typically leads to higher switching costs and stronger customer lock-in, supporting Veeva's competitive moat in the life sciences software market.
Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches
"We are excited to bring our innovative research to patients around the world with up to 25 new treatment launches by 2030. Veeva has been our global CRM standard for many years, and we are eager to build on our successful partnership and help shape the future of life sciences with a commitment to move to Veeva Vault CRM," said Uday Bose, head of human pharma global customer experience excellence and business steering at Boehringer Ingelheim. "Our goal to deliver outstanding customer experiences is shared with Veeva and our continued collaboration promises to help transform commercial operations to accelerate launch processes and drive highly personalized engagement."
Boehringer Ingelheim is seeking to expand on its existing Veeva Commercial Cloud solutions and its One Medicine and Amplify platforms, which connect development processes and data on Veeva Development Cloud.
"Boehringer Ingelheim has a forward-looking approach to unifying its technology and data landscape to rapidly deliver therapies that improve human and animal health," said Tom Schwenger, president and chief customer officer at Veeva. "I am thrilled to see our long-standing partnership expand with their move to Veeva Vault CRM."
Boehringer Ingelheim will join the opening keynote at Veeva Commercial Summit Europe, sharing how Vault CRM is a key enabler of future commercial agility, innovation, and differentiation.
Additional Information
For more on Veeva Vault CRM, visit: veeva.com/VaultCRM
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Alison Borris
Veeva Systems
925-226-8821
alison.borris@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/boehringer-ingelheim-commits-to-veeva-vault-crm-302305119.html
SOURCE Veeva Systems
FAQ
What major pharmaceutical company committed to Veeva Vault CRM in November 2023?
How many new treatments does Boehringer Ingelheim plan to launch using VEEV's platform by 2030?
What existing Veeva solutions does Boehringer Ingelheim currently use?
